NRX Pharmaceuticals

NRX Pharmaceuticals, Inc.

2 Investors

Biopharmaceuticals

WILMINGTON, DE

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for central nervous system disorders, with a particular focus on suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The company seeks to fulfill significant unmet medical needs within these areas by delivering novel treatment options that promise enhanced efficacy and safety.

Products & Team

NRX-101

Psychiatric TreatmentSeed

NRX-101 is an oral, fixed-dose combination therapy that incorporates D-cycloserine and lurasidone. It is specifically being developed for the treatment of suicidal bipolar depression and has received the esteemed FDA Breakthrough Therapy designation, which indicates its potential to offer significant improvements over existing treatment options.

Value Proposition

NRX-101 aims to provide rapid and sustained relief from the debilitating symptoms of suicidal bipolar depression, addressing a critical gap in treatment for patients experiencing acute mental health crises.

Pain Points

The primary customer pain points include the lack of effective and timely treatments for suicidal thoughts and behaviors, as well as the limitations of conventional antidepressants in addressing these urgent health issues.

Combination of D-cycloserine and lurasidoneOral administrationFDA Breakthrough Therapy designation